DAHANCA19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas

J. G. Eriksen, C. Maare, J. Johansen, H. Primdahl, J. Evensen, C. A. Kristensen, Lisbeth Juhler Andersen, J. Overgaard

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

OriginalsprogEngelsk
ArtikelnummerOC-0372
TidsskriftRadiotherapy & Oncology
Vol/bind111
Udgave nummerSuppl. 1
Sider (fra-til)154-155
ISSN0167-8140
StatusUdgivet - 2014
BegivenhedESTRO, European Society for Radiotherapy & Oncology - Vienna, Østrig
Varighed: 4 apr. 20148 apr. 2014
Konferencens nummer: 33
http://www.estro.org/congresses-meetings/items/estro-33

Konference

KonferenceESTRO, European Society for Radiotherapy & Oncology
Nummer33
LandØstrig
ByVienna
Periode04/04/201408/04/2014
Internetadresse

Citer dette

Eriksen, J. G., Maare, C., Johansen, J., Primdahl, H., Evensen, J., Kristensen, C. A., ... Overgaard, J. (2014). DAHANCA19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas. Radiotherapy & Oncology, 111(Suppl. 1), 154-155. [OC-0372].
Eriksen, J. G. ; Maare, C. ; Johansen, J. ; Primdahl, H. ; Evensen, J. ; Kristensen, C. A. ; Andersen, Lisbeth Juhler ; Overgaard, J. / DAHANCA19 : A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas. I: Radiotherapy & Oncology. 2014 ; Bind 111, Nr. Suppl. 1. s. 154-155.
@article{b304fb1ae65e40a493b63d01ce0eeb75,
title = "DAHANCA19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas",
author = "Eriksen, {J. G.} and C. Maare and J. Johansen and H. Primdahl and J. Evensen and Kristensen, {C. A.} and Andersen, {Lisbeth Juhler} and J. Overgaard",
year = "2014",
language = "English",
volume = "111",
pages = "154--155",
journal = "Radiotherapy & Oncology",
issn = "0167-8140",
publisher = "Elsevier",
number = "Suppl. 1",

}

Eriksen, JG, Maare, C, Johansen, J, Primdahl, H, Evensen, J, Kristensen, CA, Andersen, LJ & Overgaard, J 2014, 'DAHANCA19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas', Radiotherapy & Oncology, bind 111, nr. Suppl. 1, OC-0372, s. 154-155.

DAHANCA19 : A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas. / Eriksen, J. G.; Maare, C.; Johansen, J.; Primdahl, H.; Evensen, J. ; Kristensen, C. A. ; Andersen, Lisbeth Juhler; Overgaard, J.

I: Radiotherapy & Oncology, Bind 111, Nr. Suppl. 1, OC-0372, 2014, s. 154-155.

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

TY - ABST

T1 - DAHANCA19

T2 - A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas

AU - Eriksen, J. G.

AU - Maare, C.

AU - Johansen, J.

AU - Primdahl, H.

AU - Evensen, J.

AU - Kristensen, C. A.

AU - Andersen, Lisbeth Juhler

AU - Overgaard, J.

PY - 2014

Y1 - 2014

M3 - Conference abstract in journal

VL - 111

SP - 154

EP - 155

JO - Radiotherapy & Oncology

JF - Radiotherapy & Oncology

SN - 0167-8140

IS - Suppl. 1

M1 - OC-0372

ER -

Eriksen JG, Maare C, Johansen J, Primdahl H, Evensen J, Kristensen CA et al. DAHANCA19: A randomized phase III study of primary (chemo-) radiotherapy and zalutumumab in head and neck carcinomas. Radiotherapy & Oncology. 2014;111(Suppl. 1):154-155. OC-0372.